Literature DB >> 25665959

Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination.

Paul J Wichgers Schreur1, Jet Kant2, Lucien van Keulen2, Rob J M Moormann3, Jeroen Kortekaas2.   

Abstract

Rift Valley fever virus (RVFV), a mosquito-borne virus in the Bunyaviridae family, causes recurrent outbreaks with severe disease in ruminants and occasionally humans. The virus comprises a segmented genome consisting of a small (S), medium (M) and large (L) RNA segment of negative polarity. The M-segment encodes a glycoprotein precursor (GPC) protein that is co-translationally cleaved into Gn and Gc, which are required for virus entry and fusion. Recently we developed a four-segmented RVFV (RVFV-4s) by splitting the M-genome segment, and used this virus to study RVFV genome packaging. Here we evaluated the potential of a RVFV-4s variant lacking the NSs gene (4s-ΔNSs) to induce protective immunity in sheep. Groups of seven lambs were either mock-vaccinated or vaccinated with 10(5) or 10(6) tissue culture infective dose (TCID50) of 4s-ΔNSs via the intramuscular (IM) or subcutaneous (SC) route. Three weeks post-vaccination all lambs were challenged with wild-type RVFV. Mock-vaccinated lambs developed high fever and high viremia within 2 days post-challenge and three animals eventually succumbed to the infection. In contrast, none of the 4s-ΔNSs vaccinated animals developed clinical signs during the course of the experiment. Vaccination with 10(5) TCID50 via the IM route provided sterile immunity, whereas a 10(6) dose was required to induce sterile immunity via SC vaccination. Protection was strongly correlated with the presence of RVFV neutralizing antibodies. This study shows that 4s-ΔNSs is able to induce sterile immunity in the natural target species after a single vaccination, preferably administrated via the IM route.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Challenge; Four-segmented; Rift Valley fever virus; Sheep; Vaccination

Mesh:

Substances:

Year:  2015        PMID: 25665959     DOI: 10.1016/j.vaccine.2015.01.077

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Rift Valley fever: biology and epidemiology.

Authors:  Daniel Wright; Jeroen Kortekaas; Thomas A Bowden; George M Warimwe
Journal:  J Gen Virol       Date:  2019-07-16       Impact factor: 5.141

2.  Co-housing of Rift Valley Fever Virus Infected Lambs with Immunocompetent or Immunosuppressed Lambs Does Not Result in Virus Transmission.

Authors:  Paul J Wichgers Schreur; Lucien van Keulen; Jet Kant; Nadia Oreshkova; Rob J M Moormann; Jeroen Kortekaas
Journal:  Front Microbiol       Date:  2016-03-07       Impact factor: 5.640

3.  Transmission of Rift Valley fever virus from European-breed lambs to Culex pipiens mosquitoes.

Authors:  Rianka P M Vloet; Chantal B F Vogels; Constantianus J M Koenraadt; Gorben P Pijlman; Martin Eiden; Jose L Gonzales; Lucien J M van Keulen; Paul J Wichgers Schreur; Jeroen Kortekaas
Journal:  PLoS Negl Trop Dis       Date:  2017-12-27

4.  Mapping of Transcription Termination within the S Segment of SFTS Phlebovirus Facilitated Generation of NSs Deletant Viruses.

Authors:  Benjamin Brennan; Veronica V Rezelj; Richard M Elliott
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 5.  Current Status of Rift Valley Fever Vaccine Development.

Authors:  Bonto Faburay; Angelle Desiree LaBeaud; D Scott McVey; William C Wilson; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2017-09-19

6.  Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle.

Authors:  Paul J Wichgers Schreur; Nadia Oreshkova; Lucien van Keulen; Jet Kant; Sandra van de Water; Pál Soós; Yves Dehon; Anna Kollár; Zoltán Pénzes; Jeroen Kortekaas
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

Review 7.  Livestock Challenge Models of Rift Valley Fever for Agricultural Vaccine Testing.

Authors:  Andrea Louise Kroeker; Shawn Babiuk; Bradley S Pickering; Juergen A Richt; William C Wilson
Journal:  Front Vet Sci       Date:  2020-05-27

8.  Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats.

Authors:  Anna Stedman; Daniel Wright; Paul J Wichgers Schreur; Madeleine H A Clark; Adrian V S Hill; Sarah C Gilbert; Michael J Francis; Lucien van Keulen; Jeroen Kortekaas; Bryan Charleston; George M Warimwe
Journal:  NPJ Vaccines       Date:  2019-10-18       Impact factor: 7.344

9.  Increased Susceptibility of Cattle to Intranasal RVFV Infection.

Authors:  Andrea L Kroeker; Valerie Smid; Carissa Embury-Hyatt; Brad Collignon; Mathieu Pinette; Shawn Babiuk; Bradley Pickering
Journal:  Front Vet Sci       Date:  2020-04-29

Review 10.  Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile.

Authors:  Thomas P Monath; Jeroen Kortekaas; Douglas M Watts; Rebecca C Christofferson; Angelle Desiree LaBeaud; Brian Gowen; Clarence J Peters; Darci R Smith; Robert Swanepoel; John C Morrill; Thomas G Ksiazek; Phillip R Pittman; Brian H Bird; George Bettinger
Journal:  Vaccine X       Date:  2020-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.